|
Volumn 56, Issue 3, 2000, Pages 761-772
|
Progress towards the development of non-peptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: Therapeutic implications
|
Author keywords
[No Author keywords available]
|
Indexed keywords
3 (N BENZYL N METHYLAMINOMETHYL) 7 (2,6 DIFLUOROBENZYL) 4,7 DIHYDRO 2 (4 ISOBUTYRYLAMINOPHENYL) 4 OXOTHIENO[2,3 B]PYRIDINE 5 CARBOXYLIC ACID ISOPROPYL ESTER;
A 235814;
A 75998;
ABARELIX;
CETRORELIX;
GANIRELIX;
GONADORELIN;
GONADORELIN AGONIST;
GONADORELIN ANTAGONIST;
GONADORELIN RECEPTOR;
GOSERELIN;
HISTRELIN;
ITURELIX;
KETOCONAZOLE;
LEUPRORELIN;
MCN 4923;
NAFARELIN ACETATE;
QUINOLINE DERIVATIVE;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
CRYPTORCHISM;
DELAYED PUBERTY;
DRUG DESIGN;
FEMALE INFERTILITY;
HORMONAL CONTRACEPTION;
HUMAN;
HYPOGONADISM;
NONHUMAN;
OVULATION INDUCTION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
SPERMATOGENESIS;
STRUCTURE ACTIVITY RELATION;
ADMINISTRATION, ORAL;
ANIMALS;
CONTRACEPTIVE AGENTS;
FEMALE;
FORECASTING;
GONADOTROPIN-RELEASING HORMONE;
HUMANS;
MACACA FASCICULARIS;
MODELS, ANIMAL;
PROTEIN BINDING;
RATS;
RECEPTORS, GONADOTROPIN;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 0034511980
PISSN: 00071420
EISSN: None
Source Type: Journal
DOI: 10.1258/0007142001903346 Document Type: Review |
Times cited : (42)
|
References (36)
|